PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
3986.96%
Revenue growth of 3986.96% vs. zero growth in Healthcare. Walter Schloss might still want to see if it can translate into profits.
804.39%
Gross profit growth of 804.39% while Healthcare median is zero. Walter Schloss might see a slight advantage that could be built upon.
35.83%
EBIT growth of 35.83% while Healthcare median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
35.83%
Operating income growth exceeding 1.5x Healthcare median of 0.07%. Joel Greenblatt would see if unique processes drive exceptional profitability.
36.40%
Net income growth of 36.40% while Healthcare median is zero. Walter Schloss might see potential if moderate gains can keep rising.
37.84%
EPS growth of 37.84% while Healthcare median is zero. Walter Schloss might see a slight edge that could compound over time.
37.84%
Diluted EPS growth of 37.84% while Healthcare median is zero. Walter Schloss might see a slight edge that could improve over time.
2.81%
Share growth above Healthcare median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.81%
Diluted share growth above 2x Healthcare median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
-14.43%
Negative OCF growth while Healthcare median is -11.88%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-14.57%
Negative FCF growth while Healthcare median is -9.55%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1885.22%
Negative 10Y OCF/share CAGR while Healthcare median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
90.95%
OCF/share CAGR of 90.95% while Healthcare median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
81.42%
3Y OCF/share growth of 81.42% while Healthcare median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-991.23%
Negative 10Y net income/share CAGR vs. Healthcare median of 1.29%. Seth Klarman might see a fundamental problem if peers maintain growth.
94.68%
5Y net income/share CAGR > 1.5x Healthcare median of 0.45%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
84.15%
3Y net income/share CAGR of 84.15% while Healthcare median is zero. Walter Schloss might see a small advantage that can be scaled further.
1611.09%
Equity/share CAGR exceeding 1.5x Healthcare median of 48.64% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
-55.02%
Negative 5Y equity/share growth while Healthcare median is 29.26%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
127.30%
3Y equity/share CAGR > 1.5x Healthcare median of 19.73%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.25%
Assets shrink while Healthcare median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-8.96%
Negative BV/share change while Healthcare median is -5.36%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-36.45%
Debt is shrinking while Healthcare median is rising. Seth Klarman might see an advantage if growth remains possible.
-19.33%
R&D dropping while Healthcare median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-34.65%
SG&A decline while Healthcare grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.